Introduction
As the tenth anniversary of its UK launch approaches, the indications for ciprofloxacin use have widened and the dosages used increased. For example, in severe sepsis involving ICU patients in our hospital, a dosage of 400 mg iv bd is now routine. However, the debate over dosage modifications in renal failure continues. Dosage reduction of 50% has been recommended in severe renal failure both for oral doses 1,2 and for iv doses of 100 mg and 200 mg. 3, 4 The current UK data sheet recommends a 50% dosage reduction if the serum creatinine is 265 mol/L or the creatinine clearance (CrCl) is 20 mL/min. However, Brindschedler et al. 5 and Dirksen et al. 6 found no correlation between CrCl and renal clearance of ciprofloxacin and, in a previous study of 16 patients receiving iv ciprofloxacin 200 mg bd, MacGowan et al. 7 found no correlation between the CrCl and pre-dose ciprofloxacin concentrations. These findings can be explained by increased transintestinal elimination of ciprofloxacin 8 compensating for the reduced renal elimination seen in renal failure. We have, therefore, continued to use ciprofloxacin without dosage modification to treat patients with severe sepsis and renal failure. So far relatively few data on the use of iv ciprofloxacin 400 mg bd are available, but Shah et al. 9 reported that at this higher dose the CrCl could be correlated with pre-dose serum ciprofloxacin concentrations and that dosage modification is indicated. We report here a study of ciprofloxacin pharmacokinetics in 22 patients in an intensive care unit (ICU) who received iv ciprofloxacin 400 mg bd to treat known or suspected severe bacterial infection.
Materials and methods
All patients included in this survey were inpatients on the ICU at Southmead Hospital, Bristol, UK. All patients required parenteral therapy and received iv ciprofloxacin 400 mg bd unmodified for the degree of renal impairment. Any dosage modifications were made on the basis of ciprofloxacin serum concentration. Serum ciprofloxacin assays were performed by HPLC.
Results and discussion
The data from 22 patients were available for analysis, 13 males and nine females. The mean age was 60 years, range 29-76 years (Table) . Many of the patients received other antibiotics in addition to ciprofloxacin. Ten of the patients had septicaemia, four had community-acquired chest infections, three hospital-acquired chest infections and three had intra-abdominal sepsis. Almost all had underlying conditions for which they had initially been admitted. For the purpose of analysis they were divided into four groups: group 1 (n 5) had serum creatinine concentrations of 120 mol/L; group 2 (n 4) had serum creatinine concentrations 120 mol/L but did not require renal support; group 3 (n 5) required renal support but had no intra-abdominal disease; group 4 (n 8) required renal 
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support and had intra-abdominal disease. Intra-abdominal disease was defined as bowel pathology (severe diarrhoea, gut infarction, pseudomembranous colitis, peritonitis, coeliac disease) or hyperbilirubinaemia (10 the upper limit of normal) (Table) . In groups 3 and 4 two patients were receiving haemodialysis and 11 haemofiltration.
The data were analysed by an unpaired t-test to assess whether there was a significant difference between the ciprofloxacin pre-dose concentrations in patients with normal renal function compared with those with renal impairment. The data were also re-analysed using the Tukey-Kramer method 10 in order to confirm our initial findings. The median (range) of the serum creatine and the median (range) of the pre-dose ciprofloxacin concentration, respectively, for the three groups were: No significant difference was demonstrable between the concentrations of ciprofloxacin in groups 1, 2 or 3, or between those with serum creatinine above or below 265 mol/L or CrCl above or below 20 mL/min. When the patients, excluding those in group 4, were split into those patients not requiring renal support (group 1 group 2, n 9) and those who required renal support (group 3, n 5), again there was no significant difference. The median This study again supports the view that ciprofloxacin dosage modification on the basis of serum creatinine or CrCl may result in sub-therapeutic concentrations in certain patients. In addition the data underline the importance of transintestinal and biliary elimination of ciprofloxacin as a compensatory pathway for excretion of ciprofloxacin when renal impairment is present. In eight of our patients who had both renal impairment and intraabdominal disease, high ciprofloxacin concentrations were seen. We, therefore, recommend the use of iv ciprofloxacin 400 mg bd without dosage modification in renal failure unless there is co-existent bowel pathology or a high bilirubin concentration. Consideration should then be given to dosage reduction but, if possible, this should be based on assays of serum ciprofloxacin concentrations, since these vary considerably between such patients. 
